12.96MMarket Cap-1375P/E (TTM)
1.130High1.100Low5.70KVolume1.100Open1.110Pre Close6.29KTurnover0.05%Turnover RatioLossP/E (Static)11.78MShares2.00052wk High1.04P/B12.36MFloat Cap1.00052wk Low--Dividend TTM11.24MShs Float262.500Historical High--Div YieldTTM2.69%Amplitude1.000Historical Low1.103Avg Price1Lot Size
Nanoviricides Stock Forum
These guys might have the worst website I have seen since geocities. Its as if you took their code and put it into notepad.
Fortunately thats the worst experience Ive had with them. Their product is fascinating, if it really works it really could be the end ofvirus trouble. It works by mimicking human cell signatures. Fucking cool.
Update
Accesswire· 1 min ago
Way to much good unique stuff for me to post!
Let’s go
Good chart 1.26 bottom call
ready set go
Looking for 3-4 dollars
Announced that its pan-coronavirus novel Coronavirus-19 candidate NV-COV-2 has been found to be effective against SARS-COV-2 in standard cell culture pseudovirus tests, demonstrating broad-spectrum pan-coronavirus activity.
This implies that NV-COV-2 should remain active despite the constant mutation of SARS-COV-2.
I got it before platform post it
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay, demonstrating that the drug indeed has broad-spectrum pan-coronavirus activity. This pan-coronavirus activity implies that the drug NV-CoV-2 should remain active in spite of evolution of variants of SARS-CoV-2 in the field, a highly sought-after characteristic to combat the current global pandemic.
In this assay, both the drug candidate NV-CoV-2 and a positive control antibody specific to the Spike antigen S1 of the SARS-CoV-2 virus suppressed the infection by the SARS-CoV-2-pseudovirions in cell culture studies to virtually the same baseline levels.
We have now demonstrated that NV-CoV-2 is highly effective in cell cultures against SARS-CoV-2, human coronavirus NL-63, and human coronavirus 229E, all very different human coronaviruses. These results imply that the drug will remain active in spite of novel variants of SARS-CoV-2 evolution in the field, and indeed demonstrate the pan-coronavirus activity of our clinical drug candidate NV-CoV-2.
Additionally, the pseudovirion study also showed that NV-CoV-2 neutralizes the virus particles themselves, outside of the cells, validating our design mechanism.
No comment yet